|
See related Cubicin powd for inj information |
|
|
|
Manufacturer |
AstraZeneca |
|
Distributor |
Hong Kong: Zuellig/Macau: Four Star |
|
Contents |
Daptomycin |
|
Indications |
Treatment of complicated skin & skin structure infections (cSSSI) caused by susceptible isolates of the following gm+ve microorganisms: S. aureus (including methicillin-resistant isolates), Strep pyogenes, Strep agalactiae, Strep dysgalactiae subsp equisimilis & Enterococcus faecalis (vancomycin-susceptible isolates only); S. aureus bloodstream infections (bacteremia), including right-sided endocarditis caused bymethicillin-susceptible & -resistant isolates.
Click to view Cubicin detailed prescribing infomation |
|
Dosage |
cSSSI 4 mg/kg by IV infusion in 0.9% NaCl inj over a 30-min period once every 24 hr for 7-14 days. S. aureus bloodstream infections 6 mg/kg by IV infusion in 0.9% NaCl inj over a 30-min period once every 24 hr for a min of 2-6 wk. Patient w/ renal impairment CrCl <30 mL/min, including those on hemodialysis or CAPD 4 mg/kg (cSSSI) or 6 mg/kg (S. aureus bloodstream infections) once every 48 hr.
Click to view Cubicin detailed prescribing infomation |
|
Overdosage |
View Cubicin overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity to daptomycin.
Click to view Cubicin detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Cubicin detailed prescribing infomation |
|
Special Precautions |
Not indicated for treatment of pneumonia; renal impairment; pregnancy & lactation.
Click to view Cubicin detailed prescribing infomation |
|
Adverse Drug Reactions |
Constipation, nausea, diarrhea, vomiting, inj site reactions, headache, insomnia & rash.
View ADR Monitoring Form |
|
Drug Interactions |
Limited experience on use w/ warfarin & HMG-CoA reductase inhibitors.
View more drug interactions with Cubicin |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Storage |
View Cubicin storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Cubicin description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Cubicin mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
